Immunohistochemistry/IHC Market

The report "Immunohistochemistry Market by Product & Service (Antibodies (Type (Primary), Clonality (Monoclonal), Regulatory Class, Reagents, Kits, Instruments (Stainers), Software)), Application (Diagnostics (Cancer), Research, Forensics) - Global Forecast to 2030", is expected to reach USD 5.14 billion in 2030 from USD 3.55 billion in 2025, at a CAGR of 7.6% during the forecast period.

Browse 794 market data Tables and 65 Figures spread through 563 Pages and in-depth TOC on "Immunohistochemistry Market by Product & Service (Antibodies (Type (Primary), Clonality (Monoclonal), Regulatory Class, Reagents, Kits, Instruments (Stainers), Software)), Application (Diagnostics (Cancer), Research, Forensics) - Global Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/immunohistochemistry-market-121632939.html

Favorable reimbursement policies for immunohistochemistry (IHC) tests represent a significant opportunity for market growth. Comprehensive reimbursement coverage in developed nations reduces the out-of-pocket cost for patients, encouraging greater adoption of these advanced diagnostic procedures. This increased test volume directly fuels demand for IHC instruments and reagents. However, a key restraint is the complex and often inconsistent nature of reimbursement policies, which can vary significantly between regions and payers, creating uncertainty for laboratories and potentially slowing the adoption of novel, higher-cost IHC tests.

The kits segment accounted for the highest growth rate in the immunohistochemistry market, by product, during the forecast period.

By offering, the immunohistochemistry market is segmented into antibodies, reagents, kits, equipment, and software. Kits were the fastest-growing segment during the forecast period 2025-2030. This surge is driven by a significant market shift among end-users, including high-volume diagnostic laboratories, hospitals, and research institutes, toward comprehensive, standardized solutions from single, reliable providers. These users are increasingly demanding integrated kits that feature closed-system reagents and pre-calibrated quantities of all necessary components, including controls. The adoption of ready-to-use kits is particularly impactful as they streamline the entire IHC workflow. These kits drastically reduce manual preparation time by eliminating the complex and time-consuming initial steps of sourcing and validating primary antibodies and then matching them with appropriate stains. This boosts laboratory efficiency and throughput and enhances the consistency and reproducibility of results, which is a critical factor for clinical diagnostics and academic research, fueling the growth of the segment.

The hospitals & diagnostic laboratories segment accounted for the largest share of the end-user segment.

Based on end users, the immunohistochemistry market is segmented into hospitals & diagnostic laboratories, academic institutes & contract research organizations (CROs), and other end users. The hospitals & diagnostic laboratories segment accounted for the largest share of the IHC market in 2024. This is primarily due to the indispensable role of IHC in providing diagnostic precision for a wide array of diseases, most notably cancers, infectious diseases, and autoimmune disorders. The technique is fundamental for detailed tissue sample analysis in pathological examinations, enabling clinicians to study disease mechanisms and, critically, to tailor targeted treatments for patients. For instance, IHC is the gold standard for identifying protein biomarkers that guide modern cancer therapies. The growth of this segment is propelled by a confluence of powerful factors. With the global cancer burden continuing to rise, with estimates from organizations such as the WHO indicating millions of new cases diagnosed annually, the demand for reliable diagnostic tests is perpetually high. The IHC market is projected to grow at a compound annual growth rate of over 7%. Furthermore, a growing number of hospitals are establishing in-house diagnostic capabilities to offer more timely and cost-effective services. This strategic shift allows for better control over diagnostic turnaround times and helps integrate pathology more closely into the patient's treatment pathway, solidifying the leading market position of this segment.

By region, Asia Pacific accounted for the largest share of the market in 2024.

Asia Pacific dominated the market in 2024, attributed to several converging factors. Governments in the region are increasing investments in healthcare infrastructure; for instance, China's "Healthy China 2030" plan focuses on modernizing medical facilities, while India's Ayushman Bharat scheme works to expand healthcare access. Concurrently, the region is experiencing a rise in the incidence of chronic diseases, including cancer. According to the World Health Organization's International Agency for Research on Cancer, a substantial portion of new global cancer cases are diagnosed in Asia, creating a direct need for advanced pathological services such as IHC. Furthermore, the expansion of private diagnostic laboratory chains across India and Indonesia is making advanced testing more accessible.  Singapore and Thailand have also developed into centers for medical tourism, attracting international patients who require sophisticated diagnostic workups. The region has also seen an increase in contract research organizations (CROs) supporting global pharmaceutical trials, which consistently utilize IHC for tissue-based analysis. These elements collectively contribute to the elevated adoption rate and market expansion for IHC technologies throughout the Asia Pacific.

Some of the leading players in the market include F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (US), Agilent Technologies, Inc. (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Bio-Techne (US), Becton, Dickinson and Company (US), Takara Bio Inc. (Japan), PHC Holdings Corporation (Japan), Enzo Biochem Inc. (US), Sino Biological, Inc. (China), OriGene Technologies, Inc. (US), Cell Signaling Technology, Inc. (US), Bio SB (US), Miltenyi Biotec (Germany), Sakura Finetek (US), EagleBio (US), Biocare Medical LLC (US), Elabscience BioInnovation Inc. (US), Bio-Genex (US), Diagnostic BioSystems Inc. (US), Histo-Line Laboratories (Italy), Rockland Immunochemicals, Inc. (US), and CANDOR Bioscience GmbH (Germany) among others.

Don’t miss out on business opportunities in Immunohistochemistry Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/